Intravenous magnesium for cardiac arrhythmias: jack of all trades

Kwok-Ming Ho1

  • 1Department of Intensive Care, Royal Perth Hospital, Perth, Australia. kwok.ho@health.wa.gov.au

Magnesium Research
|June 18, 2008
PubMed

Insights

Intravenous magnesium effectively treats various cardiac arrhythmias by influencing the heart's electrical system. However, its efficacy varies, and further research is needed to confirm patient outcome benefits.

Area of Science:

  • Cardiology
  • Electrophysiology
  • Pharmacology

Background:

  • Intravenous magnesium is utilized for preventing and treating cardiac arrhythmias.
  • Magnesium exerts diverse electrophysiological effects on the heart's conduction system.

Purpose of the Study:

  • To review the electrophysiological actions of intravenous magnesium.
  • To summarize its reported clinical utility in various cardiac arrhythmias.
  • To identify arrhythmias where magnesium is not effective and areas for future research.

Main Methods:

  • Literature review of studies on intravenous magnesium and cardiac arrhythmias.
  • Analysis of magnesium's electrophysiological effects on cardiac conduction.
  • Synthesis of reported clinical outcomes in different arrhythmia types.

Main Results:

  • Magnesium prolongs sinus node recovery time and reduces automaticity and conduction.
  • It is effective in preventing arrhythmias post-cardiac surgery, managing atrial fibrillation, and treating specific drug-induced arrhythmias.
  • Magnesium is not effective for monomorphic ventricular tachycardia and shock-resistant ventricular fibrillation.

Conclusions:

  • Intravenous magnesium has a broad range of electrophysiological actions beneficial for certain arrhythmias.
  • Its application is established in specific clinical scenarios, but not universally.
  • Further large-scale randomized controlled studies are required to confirm its impact on patient-centered outcomes in diverse cardiac arrhythmias.

Related Concept Videos

Dysrhythmias VI: Management of Dysrhythmias01:25

Dysrhythmias VI: Management of Dysrhythmias

Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers01:20

Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers

Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Mechanism of Cardiac Arrhythmias01:28

Mechanism of Cardiac Arrhythmias

Arrhythmias are irregular heart rhythms occurring when the heart's electrical impulses become abnormal. These disturbances can lead to various symptoms, depending on their severity and the underlying cause. Some common factors contributing to arrhythmias include hypoxia, ischemia, electrolyte imbalances, excessive catecholamine exposure, drug toxicity, and muscle overstretching. Arrhythmias can be classified into two main types based on the rate and site of origin of abnormal heart rhythms.